Strive Health, an innovator in value-based kidney care, has announced a $550 million capital raise, combining $300 million in Series D equity funding with $250 million in debt financing. The equity round was led by New Enterprise Associates (NEA), with participation from CVS Health Ventures, CapitalG, Echo Health Ventures, Town Hall Ventures, Redpoint, and several new institutional investors, including funds managed by affiliates of BlackRock. Hercules Capital led the debt portion of the financing.
This substantial investment underscores growing confidence in Strive’s mission to transform kidney care through early intervention, preventative strategies, and AI-powered clinical support. With more than 35 million Americans affected by kidney disease—and 90% unaware of their condition until it reaches critical stages—Strive’s approach is designed to improve outcomes while reducing costs. The company has already demonstrated a 20% reduction in total kidney care costs and a 41% drop in hospitalizations, all while maintaining a 94% patient satisfaction rate.
Strive currently manages nearly $5 billion in annual medical spend and serves over 145,000 patients across all 50 states. Its network includes more than 6,500 provider partners, and the company has conducted over 1.3 million patient touchpoints since its founding in 2018. The new funding will support the expansion of Strive’s multi-specialty services, deepen strategic partnerships, and enhance its technology platform, CareMultiplier™, which is certified by HITRUST and central to its AI-driven care model.
The company’s team of over 700 employees—known internally as “Strivers”—will continue to focus on delivering high-touch, personalized care that integrates seamlessly with local providers. Strive’s value-based payment arrangements span commercial and Medicare Advantage payors, health systems, and physicians, offering flexible models that align incentives around patient outcomes.
With this latest round, Strive is well-positioned to scale its impact and further embed AI into chronic disease management.
KEY QUOTES:
“When we founded Strive in 2018, the team set out to transform kidney care. The continued investments from NEA, Strive’s founding capital partner, alongside a syndicate of leading financial institutions combined with valued tech and healthcare strategics, is a clear signal that the Strive team is delivering on that mission. By transforming kidney care, we will ultimately make the healthcare system work better for patients and providers.”
Chris Riopelle, Co-Founder and CEO of Strive
“We recognize that clinician-led healthcare solutions with meaningful scale are where AI implementations will have the most impact when it comes to improving outcomes for chronic disease management and preventive care — but those companies also happen to be exceedingly rare. NEA remains a proud supporter of Strive’s mission of deploying its innovative care model to slow the progression of kidney disease and we are excited at the potential for Strive’s impact to grow exponentially with this more than half a billion-dollar capital raise.”
Mohamad Makhzoumi, Co-CEO of NEA
